for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biotest AG

BIOG.DE

Latest Trade

26.20EUR

Change

0.00(0.00%)

Volume

2,187

Today's Range

25.20

 - 

26.40

52 Week Range

17.20

 - 

31.80

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
26.20
Open
26.20
Volume
2,187
3M AVG Volume
0.05
Today's High
26.40
Today's Low
25.20
52 Week High
31.80
52 Week Low
17.20
Shares Out (MIL)
39.57
Market Cap (MIL)
1,036.77
Forward P/E
-36.11
Dividend (Yield %)
--

Next Event

Biotest AG Annual Shareholders Meeting

Latest Developments

More

Biotest 9-month Adj. EBIT 9-Month Up At EUR 52 Mln

Biotest Says It Treats First COVID-19 Patient With Trimodulin

Biotest Rebukes Rumours About Acquisition Of Stakes

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Biotest AG

Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactures and markets immunoglobulin, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.

Industry

Biotechnology & Drugs

Contact Info

Landsteinerstr. 5

63303

Germany

+49.6103.8010

https://www.biotest.com/

Executive Leadership

Rolf K. Hoffmann

Chairman of the Supervisory Board

Michael Ramroth

Chairman of the Management Board, Chief Executive Officer/Chief Financial Officer

Tan Yang

Deputy Chairman of the Supervisory Board

Martin Moeller

Group Finance and Treasury Officer

Georg Floss

Chief Operating Officer, Member of the Management Board

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2018

0.4K

2020(E)

0.5K
EPS (EUR)

2018

-0.320

2020(E)

-0.720
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.23
Price To Book (MRQ)
2.32
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
105.45
LT Debt To Equity (MRQ)
103.69
Return on Investment (TTM)
-3.34
Return on Equity (TTM)
-3.03

Latest News

Latest News

BRIEF-Biotest Announces First Sales Of Human Albumin In China

* SUCCESSFULLY ENTERS CHINA, THE WORLD'S BIGGEST HUMAN ALBUMIN MARKET

BRIEF-Biotest: Zutectra Demonstrates Improved Quality Of Life In Study With Liver Transplant Patients

* BIOTEST'S ZUTECTRA(R) DEMONSTRATES IMPROVED QUALITY OF LIFE IN A STUDY WITH LIVER TRANSPLANT PATIENTS

BRIEF-Biotest Completes Phase I/III Clinical Trial With Fibrinogen

* ACHIEVES SIGNIFICANT MILESTONE BY COMPLETING PHASE I/III CLINICAL TRIAL WITH FIBRINOGEN

BRIEF-Biotest Q1 EBIT Up At EUR 1.4 Mln

* Q1 EBIT IMPROVED OVER PRIOR-YEAR PERIOD BY EUR 11.3 MILLION AND REACHED EUR 1.4 MILLION IN FIRST THREE MONTHS OF 2020

BRIEF-Polygon Says Requests Special Audit At Biotest AG

Polygon Says Requests Special Audit At Biotest AG:

BRIEF-4Sc: FDA Accepts IND Application For MERKLIN 2 Study

* INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR DOMATINOSTAT IN COMBINATION WITH AVELUMAB (BAVENCIO(R)) HAS BEEN ACCEPTED BY U.S. FOOD AND DRUG ADMINISTRATION (FDA) Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Biotest Says It Is Working On Drug Against COVID-19

* PRODUCES LIFE-SAVING MEDICINE DERIVED FROM PLASMA FROM HEALED COVID-19 PATIENTS AND PARTICIPATES IN A CROSS-INDUSTRY INITIATIVE

BRIEF-Biotest FY Loss After Tax Narrows To EUR 4.7 Million

* FY SALES FROM CONTINUING OPERATIONS 419.1 MILLION EUR VERSUS 400.3 MILLION EUR YEAR AGO

BRIEF-Biotest AG FY EBIT Turns To Loss Of EUR 1.2 Million

* FY EBIT LOSS -1.2 MILLION EUR VERSUS 10.6 MILLION EUR PROFIT YEAR AGO

BRIEF-Biotest FY Revenue Falls To EUR 378.1 Mln On Recall Of Human Albumin

* DGAP-ADHOC: BIOTEST AG: BIOTEST REACHES FY 2017 EBIT GUIDANCE

BRIEF-Biotest says Tiancheng to enter into domination agreement

* DGAP-ADHOC: BIOTEST AG: TIANCHENG INTENDS TO ENTER INTO A DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT WITH BIOTEST AG

BRIEF-Biotest: Creat Takeover Of Biotest Closed

* MAJORITY SHAREHOLDING (APPROX. 90% OF BIOTEST'S ORDINARY SHARES AND VOTING SHARE CAPITAL) OF CREAT IN BIOTEST Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Biotest sheds U.S. business to allay U.S. concerns of Chinese takeover

Biotest <BIOG.DE> said on Friday that it has sold its U.S. operations, allaying national security concerns by U.S. authorities and paving the way for the German company's sale to a Chinese investor.

BRIEF-Biotest: All Conditions Met For Creat Takeover Of Biotest

* DGAP-ADHOC: BIOTEST AG: ALL CONDITIONS MET FOR CREAT TAKEOVER OF BIOTEST

BRIEF-Biotest: Trimodulin Concept For Phase III Study Coordinated With The Authorities

* DGAP-NEWS: BIOTEST AG: TRIMODULIN: CONCEPT FOR PHASE III STUDY SUCCESSFULLY COORDINATED WITH THE AUTHORITIES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up